Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azelaic acid + salicylic acid is a topical combination therapy used primarily for the treatment of acne and related skin conditions. Azelaic acid is a dicarboxylic acid with antimicrobial and anti-inflammatory properties, effective in reducing inflammation, redness, and hyperpigmentation associated with acne and rosacea. It works by inhibiting the growth of *Cutibacterium acnes* (formerly *Propionibacterium acnes*) and normalizing keratinization. Salicylic acid is a beta-hydroxy acid (BHA) that acts as a keratolytic agent, promoting exfoliation by breaking down intercellular bonds in the stratum corneum to unclog pores and prevent new lesions. The combination leverages azelaic acid’s anti-inflammatory effects with salicylic acid’s pore-clearing action for enhanced efficacy against both inflammatory and non-inflammatory acne lesions[1][6]. This dual-action approach also helps address post-acne hyperpigmentation while minimizing irritation compared to other peeling agents[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azelaic acid + salicylic acid.